61081-34-3

Usage

Uses

Used in Pharmaceutical Industry:
1-[(methylsulfonyl)methyl]-4-nitrobenzene is utilized as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and enhancing the efficacy of existing ones. Its chemical properties allow for the creation of diverse medicinal compounds, making it a valuable asset in the pharmaceutical sector.
Used in Dye and Pigment Industry:
In the dye and pigment industry, 1-[(methylsulfonyl)methyl]-4-nitrobenzene is employed as a precursor for the production of various dyes and pigments. Its chemical structure enables the creation of a wide range of colorants, which are essential for coloring textiles, plastics, and other materials.
Used in Organic Synthesis:
1-[(methylsulfonyl)methyl]-4-nitrobenzene is used as an intermediate in organic synthesis, facilitating the production of a variety of organic compounds. Its reactivity and functional groups make it a suitable candidate for use in the synthesis of complex organic molecules, broadening its applications in the chemical industry.
Safety Considerations:

InChI:InChI=1/C8H9NO4S/c1-14(12,13)6-7-2-4-8(5-3-7)9(10)11/h2-5H,6H2,1H3

Upstream product

• 20277-69-4 sodium methansulfinate 
• 100-14-1 4-nitrobenzyl chloride 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 51392-53-1 4-nitrobenzyl methyl sulfide 
• 100-39-0 benzyl bromide 
• 77-78-1 dimethyl sulfate 
• 3112-90-1 benzyl-methyl sulfone 
• 7697-37-2 nitric acid 
• 619-75-0 1-dibromomethyl-4-nitro-benzene 
• 619-73-8 4-nitrobenzyl chloride 
• 555-16-8 4-nitrobenzaldehdye 
• 104-03-0 4-nitrobenzeneacetic acid 
• 2386-57-4 methanesulfonic acid sodium salt 

Downstream Products

• 24176-70-3 4-[(methylsulfonyl)methyl]aniline 
• 5440-67-5 2-(4-nitrobenzyl)-2-nitropropane 
• 62-23-7 4-nitro-benzoic acid 
• 82720-39-6 Acridin-9-yl-(4-methanesulfonylmethyl-phenyl)-amine; hydrochloride 
• 635702-62-4 1-[1-methyl-1-(methylsulfonyl)ethyl]-4-nitrobenzene 
• 120383-85-9 1-(cyclopropylmethyl)-4-nitrobenzene 

Relevant academic research and scientific papers

NAMPT MODULATORS

Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

An efficient approach for the synthesis of novel methyl sulfones in acetic acid medium and evaluation of antimicrobial activity

A series of nine methyl sulphones (3a-3i) starting from the aldehydes (1a-1i) were synthesized in two consecutive steps. In the first step, preparation of allyl alcohols (2a-2i) from their corresponding aldehydes by the reaction of sodium borohydride in methanol at room temperature is reported. Finally, methyl sulphones are synthesized by condensing sodium methyl sulfinates with allyl alcohols in the presence of BF3.Et2O in acetic acid medium at room temperature for about 2-3 h. The reaction conditions are simple, yields are high (85%-95%), and the products were obtained with good purity. All the synthesized compounds were characterized by their 1H, 13C NMR, and mass spectral analysis. All the title compounds were screened for antimicrobial activity. Among the compounds tested, the compound 3f has inhibited both Gram positive and Gram negative bacteria effectively and compound 3i has shown potent antifungal activity. These promising components may help to develop more potent drugs in the near future for the treatment of bacterial and fungal infections.

Heterocyclic compound and preparation and application thereof

The invention relates to bromodomain inhibitors, and provides a compound represented by a general formula I, a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method thereof, a pharmaceutical composition containing the same, and applicationthereof in pharmacy.

Copper-Mediated Decarboxylative Sulfonylation of Arylacetic Acids with Sodium Sulfinates

Herein, we present a copper-mediated decarboxylative sulfonylation of arylacetic acids with sodium sulfinates that provides viable access to sulfone compounds. This protocol features readily available feedstocks, simple operations, high regioselectivities, and moderate to good yields. The newly obtained products could be converted to other useful compounds. Importantly, the products and their derivatives exhibited potent antitumor activities in vitro, which were tested by MTT assay.

Bromine structural domain inhibitor compound and application thereof

The invention relates to a bromine structural domain inhibitor and provides a compound shown in a general formula I, pharmaceutical salt, an enantiomer, a diastereoisomer, an atropisomer, racemate, apolymorphic substance and solvate of the compound or an isotope labelled compound (including a deuterium substituted compound), a preparation method of the compound, pharmaceutical composition containing the compound and an application of the above components in pharmaceuticals.

Aniline pyrimidines, its preparation method and medical use (by machine translation)

The invention relates to: an aniline pyrimidine compound represented as the formula (I), a medicinal salt thereof, a prodrug thereof, and a hydrate or solvate thereof and also relates to: the preparation method of the compound, a medicine composition comp

Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors

Novel conformationally constrained BET bromodomain inhibitors have been developed. These inhibitors were optimized in two similar, yet distinct chemical series, the 6-methyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-ones (A) and the 1-methyl-1H-pyrrolo[2,3-c]pyridin

BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, A1, A2, A3, and A4 have any of the values defined in the specificati

DIHYDRO-PYRROLOPYRIDINONE INHIBITORS

The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, and R5 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

TETRACYCLIC BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Υ2, Υ3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).